Patent · US Active

Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto

US11633363B2 · kind B2 · utility

0Cited by

3References

12Claims

0Family size

Assignee

EMORY UNIVERSITY · US

Inventors

Lily Yang · Decatur, US
Xiangxue Guo · Lilburn, US
Hui Mao · Johns Creek, US
Wei Chen · Taipei, TW

Key dates

Filing date	Sep 27, 2018
Grant date	Apr 25, 2023
Priority date	—
Expiry date	Nov 13, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21073
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates to nanoparticles coated with fusion proteins comprising a domain that binds a cancer marker and a domain comprising a toxic polypeptide. In certain embodiments, the targeted cancer marker is urokinase plasminogen activator receptor (uPAR) insulin-like growth factor 1 receptor (IGF1R), EGFR, HER2, and/or other member of the ErbB family of receptors. In certain embodiments, the molecule that binds a cancer marker is an amino terminal fragment of uPA or variant capable of binding uPAR and/or IGF1 or variant capable of binding IGF1R. In certain embodiments, the toxic polypeptide is a bacterial exotoxin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.